resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TORC
CUSIPN/A
Phone857-315-5521
Debt
Debt-to-Equity RatioN/A
Current Ratio20.03
Quick Ratio20.04
Price-To-Earnings
Trailing P/E Ratio-1.03
Forward P/E Ratio-4.93
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($1.17) per share
Price / Book-7.38
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees7
Outstanding Shares28,050,000
Market Cap$243.16
resTORbio (NASDAQ:TORC) Frequently Asked Questions
What is resTORbio's stock symbol?
resTORbio trades on the NASDAQ under the ticker symbol "TORC."
How were resTORbio's earnings last quarter?
resTORbio, Inc. (NASDAQ:TORC) issued its quarterly earnings data on Thursday, May, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.20. View resTORbio's Earnings History.
What price target have analysts set for TORC?
4 analysts have issued twelve-month target prices for resTORbio's stock. Their predictions range from $23.00 to $36.00. On average, they anticipate resTORbio's share price to reach $29.25 in the next twelve months. This suggests a possible upside of 238.9% from the stock's current price. View Analyst Ratings for resTORbio.
What is the consensus analysts' recommendation for resTORbio?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of resTORbio's key competitors?
Some companies that are related to resTORbio include Dynavax Technologies (DVAX), Omeros (OMER), Epizyme (EPZM), TG Therapeutics Inc common stock (TGTX), CytomX Therapeutics (CTMX), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), Assembly Biosciences (ASMB), Rhythm Pharmaceuticals (RYTM), Amarin (AMRN), ANI Pharmaceuticals Inc Common Stock (ANIP), Homology Medicines (FIXX), CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT) and Inflarx (IFRX).
Who are resTORbio's key executives?
resTORbio's management team includes the folowing people:
- Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 46)
- Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 59)
- Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 50)
- Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 68)
- Ms. Susan Stewart J.D., Head of Regulatory Affairs
When did resTORbio IPO?
(TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When does the company's lock-up period expire?
resTORbio's lock-up period expires on Wednesday, July 25th. resTORbio had issued 5,666,667 shares in its public offering on January 26th. The total size of the offering was $85,000,005 based on an initial share price of $15.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Has resTORbio been receiving favorable news coverage?
News stories about TORC stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. resTORbio earned a media sentiment score of 0.17 on Accern's scale. They also assigned news coverage about the company an impact score of 47.19 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are resTORbio's major shareholders?
resTORbio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.17%). Company insiders that own resTORbio stock include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.
Which major investors are buying resTORbio stock?
TORC stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co.. Company insiders that have bought resTORbio stock in the last two years include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Insider Buying and Selling for resTORbio.
How do I buy shares of resTORbio?
Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is resTORbio's stock price today?
One share of TORC stock can currently be purchased for approximately $8.63.
How big of a company is resTORbio?
resTORbio has a market capitalization of $243.16 million. The company earns $-33,770,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis. resTORbio employs 7 workers across the globe.
How can I contact resTORbio?
resTORbio's mailing address is 500 BOYLSTON STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5521.
MarketBeat Community Rating for resTORbio (NASDAQ TORC)
MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days.
